India Pesticides Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/np9659i1qj1vzznyh260z8t9.pdf

Key Takeaways


Revenue Drivers: Domestic Surge & Volume Growth

D. K. Jain: "At least that has been our contribution for Make in India effort that we have been able to replace this product totally from import."

Shalvis Facility: The FY27 Growth Story

D. K. Jain: "We expect Shalvis revenues to be in the range of at least INR 70 crores to INR 80 crores."

Hamirpur & New Molecules

D. K. Jain: "I think even with these two new molecules, there are very few producers in India. And I think one of the products, must be, we will be the first to produce in India."

Margins & Pricing

D. K. Jain: "We have tried to pass on the cost differential to our customer, and we have been successful in convincing them for some of the products. And we feel that we should be able to maintain these prices in the coming months."

Partnerships & Capacity


Capital Allocation & Balance Sheet

D. K. Jain: "Intrinsic, if you see ultimately, the investor value will increase by conserving funds. ₹0.50 more or ₹0.25 more dividend will not significantly make investors very happy."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% to 20% increaseFY27
EBITDA margin18% to 20%FY27
Shalvis revenueAt least INR 70-80 crores (including second block)FY27
Second Shalvis block operationalCommissioningSeptember-October 2026
Working capital daysImprove by 10-12 days from 223FY27
PEDA capacity utilizationFull capacity utilizationFY27
CapexINR 45 cr (IPL) + INR 90 cr (subsidiary), funded via internal accrualsFY27
FY31 revenue targetINR 3,000 croresBy March 2031
Shalvis FY31 contributionAbout INR 1,000 croresBy March 2031
Japanese partner volumes~30% increase over prior yearFY27 and FY28

Key Metrics

MetricQ4 FY26
Consolidated revenue₹271 cr, +28.5% YoY
Domestic revenue₹183 cr, +55% YoY (vs ₹118 cr in Q4 FY25)
Export revenue₹84 cr, -5.6% YoY (vs ₹89 cr in Q4 FY25); slight decrease due to geopolitical issue in March 2026
EBITDA₹46 cr, +31.1% YoY
Net profit₹31 cr, +40.6% YoY; PAT margin 11.3%
Volume growth~30% YoY, supported by higher production levels and sustained market demand
FY26 full-year revenue₹1,078 cr, +27.9% YoY; crossed ₹1,000 cr milestone for the first time
FY26 full-year EBITDA₹194 cr, +44.7% YoY; EBITDA margin 18% (vs 15.9% in FY25)
FY26 full-year PAT₹120 cr, +45.8% YoY
FY26 product mixTechnicals ₹744 cr, Formulations ₹311 cr
FY26 domestic/export splitDomestic ₹649 cr, Export ₹408 cr (39% of total)
Net working capital days223 days, improved from 254 days in FY25
ROCE16.8%
FY27 capex budget₹45 cr (India Pesticides), ₹90 cr (100% subsidiary); funded mainly through internal accruals
FY27 revenue growth guidance15% to 20% increase expected
FY27 EBITDA margin guidance18% to 20%
Shalvis facility revenue (FY26)₹4-5 cr
Shalvis facility expected revenue (FY27)₹70-80 cr, including second block operational by Sep-Oct 2026
Pretilachlor/PEDA combined capacity8,500 metric tonnes; utilization ~70-75% due to seasonal three-month plant stop
Formulation capacity10,000 metric tonnes, distribution across 18 states via 24 depots and over 340 sales personnel
FY31 revenue target₹3,000 cr (Shalvis ~₹1,000 cr, existing plants ~₹2,000 cr)
Credit ratingA+, due for review in September
Dividend per share₹0.75